Cargando…

Rate of Recovery of Left Ventricular Ejection Fraction in a Real-World Population of Patients Receiving a Wearable Cardioverter Defibrillator

BACKGROUND: This study aimed to investigate the rate of early improvement in ejection fraction (EF) within 21 - 60 days among patients with cardiomyopathy who were provided with a wearable cardioverter defibrillator (WCD). METHODS: This was a retrospective study of patients who received a WCD at our...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abney, Lon, Coombes, Tyler, Shali, Laylan, Spoons, Jared, Mahlow, W. Jeremy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683100/ https://www.ncbi.nlm.nih.gov/pubmed/34970363 http://dx.doi.org/10.14740/cr1325

Ejemplares similares

Selection of patients eligible for implantable cardioverter defibrillator: beyond left ventricular ejection fraction
por: Rizzello, Vittoria
Publicado: (2022)

Use of the Wearable Cardioverter‐Defibrillator Among Patients With Myocarditis and Reduced Ejection Fraction or Ventricular Tachyarrhythmia: Data From a Multicenter Registry
por: El‐Battrawy, Ibrahim, et al.
Publicado: (2023)

Oversensing of the wearable cardioverter defibrillator during bipolar ventricular stimulation
por: Manninger, Martin, et al.
Publicado: (2017)

Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators
por: Mehta, Nikhil A., et al.
Publicado: (2019)

Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction
por: Jimenez-Juan, Laura, et al.
Publicado: (2017)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Appropriateness of Prescription and Safety of Wearable Cardioverter Defibrillators: A Single-center Experience
por: Sundhu, Murtaza, et al.
Publicado: (2019)

First experience with the wearable cardioverter defibrillator in the Netherlands
por: Knops, R. E., et al.
Publicado: (2011)

Wearable cardioverter defibrillator: Bridge or alternative to implantation?
por: Barraud, Jeremie, et al.
Publicado: (2017)

Multiparameter Monitoring with a Wearable Cardioverter Defibrillator
por: Rohrer, Ursula, et al.
Publicado: (2021)

Usage of the wearable cardioverter-defibrillator during pregnancy
por: Olic, J.-Jacqueline, et al.
Publicado: (2022)

Feasibility and First Results of Heart Failure Monitoring Using the Wearable Cardioverter–Defibrillator in Newly Diagnosed Heart Failure with Reduced Ejection Fraction
por: Hillmann, Henrike Aenne Katrin, et al.
Publicado: (2021)

Impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for implantable cardioverter defibrillators
por: Joshi, Subodh B, et al.
Publicado: (2011)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Magnetic Resonance Assessment of Ejection Fraction Versus Echocardiography for Cardioverter-Defibrillator Implantation Eligibility
por: Schiau, Călin, et al.
Publicado: (2021)

Physical activity is reduced prior to ventricular arrhythmias in patients with a wearable cardioverter defibrillator
por: Burch, Ashley E., et al.
Publicado: (2019)

An appropriate shock of the wearable cardioverter-defibrillator in an outpatient setting
por: Kishihara, Jun, et al.
Publicado: (2016)

Bridge to avoid ICD implantation with wearable cardioverter defibrillators
por: Zoppo, Franco, et al.
Publicado: (2020)

A Tragic Case of Wearable Cardioverter-Defibrillator Failure
por: Vinas, Ariel, et al.
Publicado: (2021)

Phantom Shocks Associated With a Wearable Cardioverter Defibrillator
por: Delle Donna, Paul, et al.
Publicado: (2021)

Experience with a Wearable Cardioverter-defibrillator in 436 Patients
por: Nägele, Herbert, et al.
Publicado: (2022)

Wearable cardioverter‐defibrillator: friend or foe in suspected myocarditis?
por: Blaschke, Florian, et al.
Publicado: (2021)

Loperamide-Induced Torsades de Pointes
por: Isang, Emmanuel, et al.
Publicado: (2021)

Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation
por: Joshi, Subodh B, et al.
Publicado: (2012)

Publisher Correction to: Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
Publicado: (2020)

Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator
por: Wan, Chingping, et al.
Publicado: (2013)

Wearable Cardioverter Defibrillator　― Initial Experience in the Outpatient Setting in Japan ―
por: Horiguchi, Ai, et al.
Publicado: (2020)

The wearable cardioverter-defibrillator is not needed for most high-risk patients
por: Bhatt, Advay G., et al.
Publicado: (2020)

The wearable cardioverter-defibrillator is needed for most high-risk patients
por: Lee, Byron K.
Publicado: (2020)

Update on Wearable Cardioverter Defibrillator: A Comprehensive Review of Literature
por: Alsamman, Mrhaf, et al.
Publicado: (2022)

Interaction between electrical storm and left ventricular ejection fraction as predictors of mortality in patients with implantable cardioverter defibrillator: A Chinese cohort study
por: Zhai, Zhengqin, et al.
Publicado: (2022)

Implantable cardioverter-defibrillator placement among patients with left ventricular ejection fraction ≤35 % at least 40 days after acute myocardial infarction
por: Judson, Gregory L., et al.
Publicado: (2022)

Does defibrillation threshold increase as left ventricular ejection fraction decreases?
por: Val-Mejias, Jesus E., et al.
Publicado: (2010)

Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator—The PROLONG Study
por: Duncker, David, et al.
Publicado: (2017)

The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital
por: Sinha, Anil-Martin, et al.
Publicado: (2020)

Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view
por: Disertori, Marcello, et al.
Publicado: (2016)

Real life experience with the wearable cardioverter-defibrillator in an international multicenter Registry
por: El-Battrawy, Ibrahim, et al.
Publicado: (2022)

A wearable cardioverter defibrillator with a low false alarm rate
por: Poole, Jeanne E., et al.
Publicado: (2022)

The wearable cardioverter‐defibrillator—Improving comfort and reaching towards noise immunity
por: Varma, Niraj
Publicado: (2022)

Epidural Blood Patch Placement with Patient Wearing Wearable Cardioverter Defibrillator: To be or Not to be
por: Gupta, Deepak
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qufqjg3104ms2hjk1n5jrmesii